# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial ap...
BTIG analyst Marie Thibault maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price target from $58 to $53.
JP Morgan analyst Robbie Marcus maintains AtriCure (NASDAQ:ATRC) with a Overweight and lowers the price target from $34 to $30.
Stifel analyst Rick Wise maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price target from $30 to $26.
Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price target from $40 to $34.
Piper Sandler analyst Matt O'Brien maintains AtriCure (NASDAQ:ATRC) with a Overweight and lowers the price target from $...
AtriCure (NASDAQ:ATRC) reported quarterly losses of $(0.17) per share which met the analyst consensus estimate. The company re...